Brady Kelly 4

What Happened
Brady Kelly, Chief Operating Officer and EVP of Seres Therapeutics (MCRB), received an award on 2026-03-04 for 56,250 derivative shares reported at $0.00. The filing identifies the award as an option (derivative) rather than a cash purchase; no immediate cash was paid and the shares are subject to vesting before Kelly can acquire them outright.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-11 (filed 7 days after the transaction). This appears later than the typical 2 business‑day Form 4 deadline.
• Instrument: Derivative award identified as an option for 56,250 shares, reported acquisition amount $0.00.
• Vesting: 25% vests on March 2, 2027; remaining shares vest in 12 equal quarterly installments thereafter (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No sale or exercise occurred—this is a compensation grant, not a market purchase or sale.

Context
This is a standard compensation-related option grant to a senior executive. Such grants do not indicate an immediate purchase or sale and generally reflect long-term incentive pay tied to continued service or performance. Because the award vests over time, the options do not provide immediate stock ownership or liquidity until vesting (and any subsequent exercise) occurs.